GlassScriptPhysician profile
Andrew Crane
NPI 1396946596
$5,922.09
in general payments reported to CMS, 2019-2025
26 companies · $1,789 in 2025
The $1,789 reported for 2025 was more than what 76% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $194 · 2020: $303 · 2021: $682 · 2022: $961 · 2023: $922 · 2024: $1,071 · 2025: $1,789.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,519 · Travel and Lodging: $1,249 · Education: $13.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,519.01 |
| Travel and Lodging | $1,249.08 |
| Education | $13.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,159.11 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Histosonics, INC. | $1,249.08 | 2025 | |
| Celgene Corporation | $982.96 | 2021-2024 | Zeposia |
| Janssen Biotech, INC. | $287.88 | 2020-2025 | Stelara, Simponi Aria, Simponi |
| Pfizer INC. | $204.04 | 2019-2025 | |
| Gilead Sciences, INC. | $200.94 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $133.19 | 2019-2025 | Eohilia, Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $112.93 | 2019-2025 | Xifaxan |
| Nestle Healthcare Nutrition INC. | $100.71 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $86.91 | 2021-2024 | Dificid |
| Mauna Kea Technologies, INC. | $47.76 | 2024 | |
| Romark Laboratories, Lc | $41.60 | 2020 | |
| Braintree Laboratories, INC. | $40.03 | 2020-2021 | |
| Lilly USA, LLC | $35.60 | 2024-2025 | Omvoh |
| Ironwood Pharmaceuticals, INC | $35.59 | 2023-2024 | Linzess |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Laborie Medical Technologies Corp. | $27.52 | 2023 | |
| Eisai INC. | $24.95 | 2022 | |
| Madrigal Pharmaceuticals | $24.54 | 2024 | Resmetirom |
| Tersera Therapeutics LLC | $23.46 | 2021 | |
| Ferring Pharmaceuticals INC. | $21.42 | 2020 | |
| Organon LLC | $18.05 | 2023 | Hadlima, Renflexis |
| Celltrion USA INC. | $17.47 | 2025 | Vegzelma |
| Allergan, INC. | $16.95 | 2020 | |
| Edwards Lifesciences Corporation | $14.98 | 2021 | |
| Ucb, INC. | $14.42 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$22,127.80 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Crane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.